Document is current
Any future updates will be listed below
-
Authors
Lv, Hua-Kun
Chen, Xu
Xing, Bo
Hu, Xiao-Song
Zhang, Xin-Pei
Shen, Yu-Gang
Wang, Yan
Liu, Miao-Miao
Chen, Ying-Ping
Liang, Zhen-Zhen
Mao, Yu
-
Funding
Funding for this research was provided by:
Liaoning Chengda Biological Limited by Share Ltd
- License Information
-
More Information
Article History
Received: 10 October 2024
Accepted: 28 January 2025
First Online: 27 February 2025
Declarations
:
: This clinical trial was approved by Institutional Review Board (IRB) of Zhejiang Provincial Center for Disease Control and Prevention (approval number: 2021-001-01), and adhered to the Good Clinical Practice (GCP), Declaration of Helsinki, and Chinese regulatory requirements. All participants and their guardians (for the participants aged 10–17 years) were fully informed before screening. Written informed consent was obtained from the participants (if aged 18–60 years) or the participants (if aged 10–17 years) and their guardians prior to study screening.
: Miaomiao Liu, Yan Wang and Yu Mao are the employees of Liaoning Chengda Biological Limited by Share Ltd, the other authors had no conflicts of interest to declare.
